Evidence map›Paper›PMID 42757550›Full record

ArticleThe Kaohsiung journal of medical sciences2026

SOX2 Inhibits Cuproptosis to Affect Cisplatin Resistance in Non-Small Cell Lung Cancer by Activating the Wnt/ATP7B Signaling Pathway.

Kun Chen, Fu-Mei He, Ying-Hui Huang, Ting Fang, Yi-Ping Zheng, Jian-Feng Cai

Abstract read
In one paragraph

Article in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kun ChenPulmonary and Critical Medicine, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian, China.
Fu-Mei HePulmonary and Critical Medicine, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian, China.
Ying-Hui HuangPulmonary and Critical Medicine, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian, China.
Ting FangPulmonary and Critical Medicine, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian, China.
Yi-Ping ZhengPulmonary and Critical Medicine, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian, China.
Jian-Feng CaiPulmonary and Critical Medicine, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian, China.ORCID https://orcid.org/0009-0003-5754-8122

Funding

Natural Science Fund Project of Fujian Province 2024J011610
6 · The paper itself

Abstract

Cisplatin (CDDP) resistance constitutes the principal clinical challenge in the treatment of advanced non-small cell lung cancers (NSCLC). Disturbances in copper metabolism are closely linked with tumor drug resistance. SOX2, a pivotal stemness transcription factor (TF), holds an important role in chemotherapy resistance. However, whether it influences CDDP resistance by modulating cuproptosis remains unknown. SOX2 level was tested by qPCR and WB, and ATP7B level was evaluated by WB and flow cytometry. The oligomerization levels of FDX1, LIAS, and DLAT, together with Cu

Indexed as

ATP7Bcisplatin resistancecuproptosisSOX2Wnt pathway

Identifiers

PMID42757550
PMCPMC13587018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.